BridgeMD
Tests treatment safety and results for Ulcerative Colitis
Official title A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
ClinicalTrials.gov ID: NCT06979336
What this study is testing
What is RO7837195?
RO7837195 is an investigational medicine, being studied as a potential treatment for ulcerative colitis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Diagnosis of ulcerative colitis (UC) established at least 3 months
- Moderately to severely active UC assessed by mMS
- Inadequate response, loss of response, or intolerance to conventional or advanced therapies for UC
You likely can't join if
- Prior extensive colonic resection, subtotal or total colectomy, or planned surgery for UC
- Diagnosis of Crohn's disease or indeterminate colitis
- Treatment with an advanced therapy targeted at tumor necrosis factor-like cytokine 1A (TL1a)
- Inadequate response, loss of response, or intolerance to treatment of UC with an advanced therapy targeted at IL-12 and/or IL-23
The study team makes the final eligibility decision.
Where it's taking place
- Lancaster, California, United States
- San Diego, California, United States
- Colorado Springs, Colorado, United States
- Kissimmee, Florida, United States
- Chicago, Illinois, United States
- Fresh Meadows, New York, United States
- Monroe, North Carolina, United States
- Salt Lake City, Utah, United States
- South Brisbane, Queensland, Australia
- Fortaleza, Ceará, Brazil
- Brasília, Federal District, Brazil
- Belo Horizonte, Minas Gerais, Brazil
- Curitiba, Paraná, Brazil
- Porto Alegre, Rio Grande do Sul, Brazil
- Aracaju, Sergipe, Brazil
- Ja, São Paulo, Brazil
- Santo André, São Paulo, Brazil
- São José do Rio Preto, São Paulo, Brazil
- São Paulo, São Paulo, Brazil
- So Paulo, São Paulo, Brazil
+ 64 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lancaster, California, United States; San Diego, California, United States; Colorado Springs, Colorado, United States; Kissimmee, Florida, United States; Chicago, Illinois, United States; Fresh Meadows, New York, United States and 78 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.